Filtered By:
Condition: Antiphospholipid Syndrome

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 523 results found since Jan 2013.

Lupus anticoagulant and ischemic strokes: about two case reports
We report here two cases of stroke associated with the presence of LA, and recall the strategy for screening for LA.PMID:34427558 | DOI:10.1684/abc.2021.1662
Source: Annales de Biologie Clinique - August 24, 2021 Category: Biochemistry Authors: Julie Hilaire Clara Noizat Minh-Toan Duong Maxime Delrue Dominique Herv é Alain Stepanian Marie Neuwirth Arezki Hadj-Ali B érangère S Joly Agn ès Veyradier Virginie Siguret Nicolas B éranger Source Type: research

Direct oral anticoagulant use in special populations
Purpose of review The pivotal phase III trials demonstrating efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of venous thromboembolism (VTE) or nonvalvular atrial fibrillation (NVAF) excluded patients with important and common comorbidities, including obesity, advanced chronic kidney disease, cirrhosis, cancer and antiphospholipid antibody syndrome. Despite the lack of large prospective randomized control trials in these patient populations, the use of DOACs has led to a wealth of efficacy and safety data within these groups. Recent findings Retrospective studies, meta-analyses, nation...
Source: Current Opinion in Pulmonary Medicine - August 11, 2021 Category: Respiratory Medicine Tags: DISORDERS OF THE PULMONARY CIRCULATION: Edited by Steven D. Nathan, Christopher King and Oksana A. Shlobin Source Type: research

Antiphospholipid Syndrome-induced Ischemic Stroke Following Pembrolizumab: case report and systematic review
We report a case of a patient treated with pembrolizumab who developed an acute ischemic stroke (AIS) as manifestation of immunotherapy-induced antiphospholipid syndrome (APS) and provide a systematic review of the literature.
Source: Lung Cancer - August 3, 2021 Category: Cancer & Oncology Authors: Vito Tota, Marie Dagonnier, Didier Wery, Laure Binet, Nathalie Nagy, Val érie Durieux, Marie Diaz, Jose-Antonio Elosegi, Stéphane Holbrechts Tags: Review Source Type: research

Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19
CONCLUSIONS: COVID-19 patients rapidly expand B1a cells secreting pathogenic lipid-binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity and mortality suggests a causal role of aPL in COVID-19 associated coagulopathy.PMID:34242469 | DOI:10.1111/jth.15455
Source: Thrombosis and Haemostasis - July 9, 2021 Category: Hematology Authors: Anne Hollerbach Nadine M üller-Calleja Denise Pedrosa Antje Canisius Martin F Sprinzl Tanja Falter Heidi Rossmann Marc Bodenstein Christian Werner Ingo Sagoschen Thomas M ünzel Oliver Schreiner Visvakanth Sivanathan Michael Reuter Johannes Niermann Pete Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Neurologic Manifestations of the Antiphospholipid Syndrome - an Update
Curr Neurol Neurosci Rep. 2021 Jun 14;21(8):41. doi: 10.1007/s11910-021-01124-z.ABSTRACTPURPOSE OF REVIEW: In recent years, the spectrum of neurological manifestations of antiphospholipid syndrome (APS) has been growing. We provide a critical review of the literature with special emphasis on presentation, proposed mechanisms of disease, and treatment of neurological involvement in APS.RECENT FINDINGS: Although stroke is the most common cause of neurological manifestations in patients with APS, other neurological disorders have been increasingly associated with the disease, including cognitive dysfunction, headache, and epi...
Source: Epilepsy Curr - June 14, 2021 Category: Neurology Authors: Miguel Leal Rato Matilde Bandeira Vasco C Rom ão Diana Aguiar de Sousa Source Type: research

Neurologic Manifestations of the Antiphospholipid Syndrome — an Update
AbstractPurpose of ReviewIn recent years, the spectrum of neurological manifestations of antiphospholipid syndrome (APS) has been growing. We provide a critical review of the literature with special emphasis on presentation, proposed mechanisms of disease, and treatment of neurological involvement in APS.Recent FindingsAlthough stroke is the most common cause of neurological manifestations in patients with APS, other neurological disorders have been increasingly associated with the disease, including cognitive dysfunction, headache, and epilepsy. Direct oral anticoagulants have failed to show non-inferiority compared to vi...
Source: Current Neurology and Neuroscience Reports - June 14, 2021 Category: Neuroscience Source Type: research